ALTANA Pharma and Atugen Renew Target Validation and License Agreement
Atugen uses a unique target validation approach where both siRNA molecules and a third generation antisense technology (GeneBloc®) are employed in parallel. This approach, called CrossValidation, is designed to exclude artifacts and nonspecific effects that could arise if either technology were applied alone. The GeneBloc® technology is, in contrast to other antisense technologies, extremely potent and devoid of toxicity. Furthermore, Atugen possesses a set of proprietary liposomal transfection reagents that is custom-tailored to individual cell lines and minimizes toxicity while obtaining high transfection rates.
Atugen's gene silencing technologies are employed in in vitro and in vivo target validation and the Company has a program to develop siRNA therapeutics.
Most read news
Topics
Organizations
Other news from the department business & finance
Get the analytics and lab tech industry in your inbox
From now on, don't miss a thing: Our newsletter for analytics and lab technology brings you up to date every Tuesday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.